TD Asset Management
RYZB

TD Asset Management’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

TD Asset Management’s Portfolio RYZB Stock Details RYZB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-72,610
Closed -$1.61M – 1467
2023
Q3 		$1.61M Buy
+72,610
New +$1.52M ﹤0.01% 1016

Other funds holding RYZB

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TD Asset Management's RYZB Position: Q4 2023 in Review

TD Asset Management sold out of RayzeBio, Inc. Common Stock (RYZB) in Q4 2023, closing a stake of 72,610 shares — an estimated $1.61M sold.

TD Asset Management first reported a position in RYZB in Q3 2023 and held it in 1 quarter. The position peaked at $1.61M in Q3 2023. 107 funds tracked by Wall St. Rank hold RYZB as of Q4 2023.

  • TD Asset Management reported no remaining RayzeBio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • TD Asset Management sold 72,610 RayzeBio, Inc. Common Stock shares in Q4 2023, an estimated $1.61M.
  • TD Asset Management first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • TD Asset Management's RayzeBio, Inc. Common Stock position peaked at $1.61M in Q3 2023.
  • 107 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q4 2023.

Based on TD Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.